Pycnogenol: A nutraceutical for venous health

Biomedical Reviews

Volumn 19, Issue , 2008, Pages 33-43

  Gulati, Om P ^a  

^a Horphag Research   (Switzerland)

Author keywords

Chronic venous insufficiency; Food supplement; Nutrigenomics

Indexed keywords

EID: 80051503983     PISSN: 1310392X     EISSN: None     Source Type: Journal    
DOI: 10.14748/bmr.v19.59     Document Type: Article

References (84)

1. Mariman EC. Nutrigenomics in perspective. Pharmacogenomics 2007;8: 421-424.
2. Maritime Pine Extract. United States Pharmacopoeia - National Formulary. Volume USP 30 - NF 25. Rockville: United States Pharmacopeial Convention, Inc; 2007. p 965-966.
3. Borzelleca JF, Burdock GA, Thomas JA. Opinion of an expert panel on the Generally Recognized As Safe (GRAS) status of French maritime pine bark extraxt (Pycnogenol(R)) as a flavoring agent. Internal document 2003.
4. ®, French Maritime Pine Bark Extract. Encyclopedia of Dietary Supplements. New York: Marcel Dekker Inc., 2005. p 545-553.
5. Drehsen G. From ancient pine bark uses to Pycnogenol. In: Packer L, Hiramatsu M, Yoshikawa T, editors. Antioxidant Food Supplements in Human Health. Academic Press; 1999. p 311-322.
6. Gulati OP. The nutraceutical Pycnogenol: its role in cardiovascular health and blood glucose control. Biomed Rev 2005;16:49-57.
7. Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia 2000;71:236-244.
8. Petrassi C, Mastromarino A, Spartera C. Pycnogenol in chronic venous insufficiency. Phytomedicine 2000;7:383-388.
9. Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res 2002;16 (Suppl 1):S1-5.
10. Schmidtke I, Schoop W. Le pycnogénol: Thérapeutique médicamenteuse de l'oedème statique. J Suisse Méd Globale 1995;3:114-115.
11. Schmidtke I, Schoop W. Das hydrostatische Ödem und seine medikamentöse Beeinflussung. Swiss Med 1984;6:67-69.
12. Becker SR. Le pycnogénol: une substance douée de properiétés angioprotectrices dans le traitement de l'insuffisance veineuse chronique. J Suisse Méd Globale 1995;95:11-14.
13. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 2006;12:205-212.
14. Vinciguerra G, Belcaro G, Cesarone MR, Rohdewald P, Stuard S, Ricci A, et al. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006;57:331-339.
15. ® in venous disorders: A review. Eur Bull Drug Res 1999;7: 8-13.
16. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-168.
17. Blumenthal M. Pycnogenol (French Maritime Pine Bark Extract) Pinus Pinaster Aiton subsp. Atlantica. The American Botanical Council guide to Herbs; 2003. p 369-373.
18. Wenner A, Leu HJ, Spycher MA, Brunner U. Ultrastructural changes of capillaries in chronic venous insufficiency. Exp Cell Biol 1980;48:1-14.
19. Bollinger A, Jager K, Geser A, Sgier F, Seglias J. Transcapillary and interstitial diffusion of Na-fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc Clin Exp 1982;1:5-17.
20. Nicolaides AN. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). Circulation 2000;102:E126-E163.
21. Stucker M, Falkenberg M, Reuther T, Altmeyer P, Lubbers DW. Local oxygen content in the skin is increased in chronic venous incompetence. Microvasc Res 2000;59:99-106.
22. Flore R, Gerardino L, Santoliquido A, Pola R, Flex A, di Campli C, Pola P, Tondi P. Enhanced oxidative stress in workers with a standing occupation. Occup Environ Med 2004;61:548-550.
23. Nordmann H, Gulati OP. Acute venous stasis and chronic venous insufficiency models in rats. Methods Find Exp Clin Pharmacol 1983;5:347-355.
24. Nordmann H, Gulati OP. Hemodynamic studies in acute venous stasis edema in rats. Experientia 1984;40(4):346-348.
25. Gulati OP, Sharma SC, Hammersen F. Hemodynamic, biochemical and morphological changes in the dextran and D-galactosamine-induced edemas in rats. Arch Int Pharmacodyn Ther 1983;263(2):272-287.
26. Gulati OP, Malmsten C, Ponard G, Gulati N. The local edemogenic effects of leukotriene C4 and prostaglandin E2 in rats. Prostaglandins Leukot Med 1983;10:11-17.
27. ® am Modell der akuten venösen Stauung an der Ratte. Swiss Med 1984;6:63-66.
28. Sharma SC, Gulati OP. Role of calcium in the histamine release induced by D-galactosamine from rat mast cells. Experientia 1985;41:1177-1178.
29. Belkhiri A, Richards C, Whaley M, McQueen SA, Orr FW. Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest 1997;77:533-539.
30. Widmer LK, Stahelin HB, Nissen C, da Silva A. Venen- Arterienkrankheiten, Koronare Herzkrankheit bei Berufstätigen. Bern, Stuttgart, Wien: Verlag Hans Huber; 1981.
31. Leu AJ, Leu HJ, Franzeck UK, Bollinger A. Microvascular changes in chronic venous insufficiency - a review. Cardiovasc Surg 1995;3:237-245.
32. Junger M, Steins A, Hahn M, Hafner HM. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 2000;7:S3-S12.
33. Wollina U, Abdel-Naser MB, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds 2006;5:169-180.
34. Junger M, Hahn M, Klyscz T, Steins A. Microangiopathy in the pathogenesis of chronic venous insufficiency. Curr Probl Dermatol 1999;27:124-129.
35. Bergan JJ, Schmid-Schonbein GW. Therapeutic management of chronic venous insufficiency: microcirculation as a target. Microcirculation 2000;7(6 Pt 2):S23-S28.
36. Virgili F, Kim D, Packer L. Procyanidins extracted from pine bark protect alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 1998;431:315-318.
37. Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radic Biol Med 1999;27:704-724.
38. Virgili F, Kobuchi H, Noda Y, Cossins E, Packer L. Procyanidins from Pinus maritima bark: Antioxidant activity, effects on the immune system and modulation of nitrogen monoxide metabolism. In: Packer L, Hiramatsu M, Yoshikawa T, editors. Antioxidant Food Supplements in Human Health. Academic Press; 1999. p 323-342.
39. ® as an adjunct in the management of childhood asthma. J Asthma 2004;41:825-832.
40. Blazso G, Gabor M, Sibbel R, Rohdewald P. Anti-inflammatory and superoxide radical scavenging activities of procyanidins containing extract from the bark of Pinus pinaster sol. and its fractions. Pharm Pharmacol Lett 1994;3:217-220.
41. Rong Y, Li L, Shah V, Lau BH. Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Biotechnol Ther 1995;5:117-126.
42. Noda Y, Anzai K, Mori A, Kohno M, Shinmei M, Packer L. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997;42:35-44.
43. Nelson AB, Lau BH, Ide N, Rong Y. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical-induced DNA damage. Drug Dev Ind Pharm 1998;24:139-144.
44. Chida M, Suzuki K, Nakanishi-Ueda T, Ueda T, Yasuhara H, Koide R, et al. In vitro testing of antioxidants and biochemical end-points in bovine retinal tissue. Ophthalmic Res 1999;31: 407-415.
45. Cossins E, Lee R, Packer L. ESR studies of vitamin C regeneration, order of reactivity of natural source phytochemical preparations. Biochem Mol Biol Int 1998;45:583-597.
46. Kim J CJ, Pinnas JL, Mooradian AD. Effect of selected antioxidants on malondialdehyde modification of proteins. Nutrition 2000;16:1079-1081.
47. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000;57:834-841.
48. Sharma SC, Sharma S, Gulati OP. Pycnogenol prevents haemolytic injury in G6PD deficient human erythrocytes. Phytother Res 2003;17:671-674.
49. Bayeta E BM, Lau HS. Pycnogenol inhibits generation of inflammatory mediators in macrophages. Nutr Res 2000;20:249-259.
50. ©enhances endothelial cell antioxidant defenses. Redox Report 1997;3:219-224.
51. Saliou C, Rimbach G, Moini H, McLaughlin L, Hosseini S, Lee J, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med 2001;30:154-160.
52. Sime S, Reeve VE. Protection from inflammation, immunosuppression and carcinogenesis induced by UV radiation in mice by topical Pycnogenol. Photochem Photobiol 2004;79:193-198.
53. Blazso G, Rohdewald P, Sibbel R, Gabor M. Anti-inflammatory activities of procyanidin-containing extracts from Pinus pinaster sol. In: Antus S, Gabor M, Vetschera K, editors; 1995 July 16-19; Vienna, Austria. p 231-238.
54. Blazso G, Gabor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 1997;52:380-382.
55. Cho KJ, Yun CH, Packer L, Chung AS. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 2001;928:141-156.
56. Grimm T, Schafer A, Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 2004;36:811-822.
57. Sharma SC, Sharma S, Gulati OP. Pycnogenol inhibits the release of histamine from mast cells. Phytother Res 2003;17:66-69.
58. Blazso G, Gabor M, Schonlau F, Rohdewald P. Pycnogenol accelerates wound healing and reduces scar formation. Phytother Res 2004;18:579-581.
59. Belcaro G, Cesarone MR, Errichi BM, Ledda A, di Renzo A, Stuard S, et al. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005;56:699-705.
60. Maritim A, Dene BA, Sanders RA, Watkins JB, 3rd. Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2003;17:193-199.
61. Berryman AM, Maritim AC, Sanders RA, Watkins JB, 3rd. Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol 2004;18:345-352.
62. Dene BA, Maritim AC, Sanders RA, Watkins JB, 3rd. Effects of antioxidant treatment on normal and diabetic rat retinal enzyme activities. J Ocul Pharmacol Ther 2005;21:28-35.
63. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-934.
64. Durackova Z, Trebaticky B, Novotny V, Zitnanova I, Breza J. Lipid metabolism and erectile function improvement by Pycnogenol, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction- a pilot study. Nutr Res 2003;23:1189-1198.
65. Segger D, Schonlau F. Supplementation with Evelle improves skin smoothness and elasticity in a double-blind, placebo-controlled study with 62 women. J Dermatolog Treat 2004;15:222-226.
66. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res 2002;16:567-571.
67. Roseff SJ. Improvement in sperm quality and function with French maritime pine tree bark extract. J Reprod Med 2002;47:821-824.
68. Kohama T, Suzuki N, Ohno S, Inoue M. Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial. J Reprod Med 2004;49: 828-832.
69. © chewing gum minimizes gingival bleeding and plaque formation. Phytomedicine 2002;9: 410-413.
70. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ippolito E, Scoccianti M, et al. Prevention of edema in long flights with Pycnogenol. Clin Appl Thromb Hemost 2005;11:289-294.
71. Belcaro G, Cesarone MR, Rohdewald P, Ricci A, Ippolito E, Dugall M, et al. Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol. Clin Appl Thromb Hemost 2004;10:373-377.
72. Kohama T. Nutritional supplements in clinical practice. Prog Med 2004;24:1503-1510.
73. ®- the rationale of its use as a food supplement in traveller's thrombosis and motion sickness. Phytother Res 2004;18:687-695.
74. ®- its use as a food supplement in traveller's thrombosis, oedema and motion sickness. Eur Bull Drug Res 2005;13:77-81.
75. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 2006;57:569-576.
76. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR. Pine bark extract reduces platelet aggregation. Integr Med 2000;2:73-77.
77. Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res 2001;21:1251-1260.
78. Fitzpatrick DF, Bing B, Rohdewald P. Endotheliumdependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 1998;32:509-515.
79. Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992;86:1302-1309.
80. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993;334:170-174.
81. Chaldakov GN. Cardiovascular adipobiology: a novel. Heart-associated adipose tissue in cardiovascular disease. Ser J Exp Clin Res 2008; 9: 81-88.
82. Watson RR. Reduction of cardiovascular disease risk factors by French Maritime Pine Bark Extract. Cardiovasc Rev Reports 1999; 20:326-329.
83. Putter M, Grotemeyer KH, Wurthwein G, Araghi-Niknam M, Watson RR, Hosseini S, et al. Inhibition of smokinginduced platelet aggregation by aspirin and pycnogenol. Thromb Res 1999;95:155-161.
84. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR. Pine bark extract reduces platelet aggregation. Integr Med 1999;2:73-77.